Harrow Health, Inc. Stock News

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2...

Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Ope...

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockhold...

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the lead...

Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, especially VEVYE, are driving a diversified revenue stream, with VEVYE showing exceptional growth and market penetration since its late 2023 launch. VEVYE's strong refill rates and expanding prescriber ba...

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow's ophthalm...

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website...

There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.